Mohammed Kashani-Sabet

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant
    Ineligible company: 
    Bristol-Myers Squibb
    Topic: 
    Melanoma Advisory Board
    Date added: 
    04/16/2023
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    12/31/2021
    Date reviewed: 
    07/27/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Stock
    Ineligible company: 
    Melanoma Diagnostics
    Date added: 
    04/16/2023
    Mitigation strategy: 
    Divest
    Relationship end date: 
    12/31/2021
    Date reviewed: 
    07/27/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Stock
    Ineligible company: 
    DNArx, LLC
    Date added: 
    04/16/2023
    Mitigation strategy: 
    Divest
    Relationship end date: 
    04/16/2023
    Date reviewed: 
    07/27/2023
Return to 0102_SHVGR_Melanoma Trends and Medical Advances_Live